Friday, June 6, 2025

Monthly Archives: June, 2020

COVID-19 significantly impacts health services for noncommunicable diseases

June 01, 2020: "Prevention and treatment services for noncommunicable diseases (NCDs) have been severely disrupted since the COVID-19 pandemic began, according to a WHO...

Lynparza recommended for approval in EU by CHMP

June 01, 2020: "AstraZeneca and MSD announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line maintenance treatment...

Chi-Med Plans to Submit NDA for Surufatinib Following Pre-NDA Meeting with the U.S. FDA

June 1, 2020: "Hutchison China MediTech Limited announces that it has held its pre-New Drug Application meeting with the U.S.FDA for surufatinib for the treatment...

World’s First Study of a Potential COVID-19 Antibody Treatment in Humans

June 1, 2020: "Eli Lilly and Company announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight...

FDA Ok’s Lilly’s Taltz® for the Treatment of Non-Radiographic Axial Spondyloarthritis

June 1, 2020: Eli Lilly and Company announced that U.S.FDA has approved a supplemental Biologics License Application (sBLA) for Taltz® (ixekizumab) injection 80 mg/mL for the...

CytoDyn Files Request With FDA for Priority Review of BLA for First Approval

June 01, 2020: "CytoDyn announced that it has filed with the U.S. FDA a request seeking Priority Review designation for the Company’s Biologics License...
- Advertisment -

Most Read